Sosei Heptares, a biopharmaceutical company, agreed to acquire the Asia Pacific business of Idorsia, a Swiss pharmaceutical research company, for $462m. “We have patiently and diligently been searching for the right opportunity to accelerate our mission to deliver life-changing new medicines to patients. This transaction with Idorsia is truly transformational and achieves one of our key strategic objectives, establishing Sosei Heptares as a fully integrated Japan-focused pharmaceutical business, with growing commercial sales and an expected new product launch next year. The addition of a highly experienced clinical development and entrepreneurial commercial team in Japan led by Dr Satoshi Tanaka, one of the country’s most successful drug developers in recent times, fast-tracks our vision to become one of Japan’s global biopharmaceutical champions," Chris Cargill, Sosei Heptares President and CEO.